PROGRESS

In The Control Of Pancreatic Insufficiency



creon®

pancreatin

RIGHT ON TARGET - RIGHT FROM THE START

Prescribing Information – Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc: Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar Further information is available from:
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.

CRAd/PEI/1/89

THE QUALITIES OF LEADERSHIP

Experience
Unique among foam treatments, Colifoam has over 12 years of proven efficacy and safety in clinical practice.

Trust
Equally as effective as steroid enemas,[1,2] Colifoam is well documented and is the most prescribed topical treatment[3] for ulcerative colitis.

Confidence
Colifoam's simplicity and effectiveness has transformed the lives of thousands of patients, enabling them to pursue active social and working lives.[1]

COLIFOAM
10% Hydrocortisone acetate foam.

The leading topical treatment for ulcerative colitis.

PRESCRIBING INFORMATION: Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10%. Uses: Ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration: One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). Contra-indications, warnings etc.: Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions: Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. Legal category: POM. Package Quantity & Basic NHS cost: 25g canister plus applicator, £7.25. Further Information: One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No.: 0036/0021. References 1. Somerville KW et al. British Medical Journal 1985; 291:866. 2. Ruddell WSJ et al. Gut 1980; 21:885-889. 3. Independent Research Audit. Data on File. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Broadwater Road, Welwyn Garden City, Herts. AL7 3SP.

Quite simply

A SUPERIOR CHOICE TO H_2-ANTAGONISTS*[1-3]
in erosive oesophagitis



67%
healed on **LOSEC**
20mg once daily[1]
in 4 weeks

31%
healed on ranitidine
150mg bd[1]
in 4 weeks

The figures speak for themselves

ONCE DAILY

*Conventional starting courses of ranitidine or cimetidine in erosive reflux oesophagitis (March 1990)

n = 152[1]

omeprazole-Astra

1. Sandmark S et al. Scand J Gastroenterol 1988; **23**: 625-32. 2. Zeitoun P et al. Lancet 1987; **II**: 621-2. 3. Bate CM et al. Gut 1989; **30**: A1493-4.

Abbreviated Prescribing Information

Presentation: Losec capsules containing 20mg omeprazole. **Indications:** Healing of erosive reflux oesophagitis. Symptom relief is rapid, and the majority of patients are healed after 4 weeks. **Dosage:** Adults (including elderly): 20mg Losec once daily, given for 4 weeks. For those patients not fully healed after the initial course, healing usually occurs during a further 4 weeks' treatment. Losec has also been used in a dose of 40mg once daily in patients with reflux oesophagitis refractory to other therapy. Healing usually occurred within 8 weeks. Long-term maintenance treatment with Losec is not recommended. *Children*: There is no experience of the use of Losec in children. *Impaired renal or hepatic function*: Adjustment is not required. Patients with severe liver disease should not require more than 20mg Losec daily. **Contra-indications, Warnings, etc:** No known contra-indications to the use of Losec. When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with Losec is instituted, as treatment may alleviate symptoms and delay diagnosis. Avoid in pregnancy unless there is no safer alternative. Breast feeding should be discontinued if the use of Losec is considered essential. Losec is well tolerated. Nausea, headache, diarrhoea, constipation and flatulence have been reported but are rare. Skin rashes have occurred in a few patients. These events have usually been mild and transient and there has been no consistent relationship with treatment. Losec can delay the elimination of diazepam, phenytoin and warfarin. Monitoring of patients receiving warfarin or phenytoin is recommended and a reduction of warfarin or phenytoin dose may be necessary when omeprazole is added to treatment. No evidence of an interaction with theophylline, propranolol or antacids. *Animal Toxicology*: Gastric ECL-cell hyperplasia and carcinoids, localised to the oxyntic mucosa, have been observed in life-long studies in rats. These changes have been related to sustained hypergastrinaemia. No treatment related mucosal changes have been observed in patients treated continuously for periods up to 4 years. **Pharmaceutical Precautions:** Use within one month of opening. Replace cap firmly after use. Dispense in original containers. **Legal Category:** POM. **Package Quantities and Basic NHS Cost:** Bottles of 5 capsules, £6.49; Bottles of 28 capsules, £30.36. **Product Licence Number:** PL0017 0238. **Product Licence Holder:** Astra Pharmaceuticals Ltd, Home Park Estate, Kings Langley, Herts WD4 8DH.

ASTRA

For further information please contact
Astra Pharmaceuticals Ltd
Telephone: (0923) 266191

Losec is a registered trade mark

Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.

colofac®

mebeverine

loosens the grip of IBS

Prescribing Information

Presentation: White, sugar-coated tablets each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. Yellow, banana-flavoured sugar-free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml: Basic NHS price £3.50. **Indications:** 1. Irritable bowel syndrome. 2. Gastrointestinal spasm secondary to organic diseases. **Dosage and Administration:** Tablets: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. Suspension: Adults and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-indications, warnings, etc:** Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** *Tablets:* 0512/0044: *Suspension:* 0512/0061. Further information is available on request to the Company.

duphar Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Telephone: 0703 472281

C/Hosp Ad/1/88

FAST WORKER

PEPCID® PM 40

(famotidine) *mg*

ONE AT NIGHT CAN MAKE THEIR DAY

Abridged Product Information

Refer to Data Sheet before prescribing.

INDICATIONS Duodenal ulcer; prevention of relapses of duodenal ulceration; benign gastric ulcer; hypersecretory conditions such as Zollinger-Ellison syndrome.

DOSAGE In duodenal and benign gastric ulcer, 40 mg at night for four to eight weeks. For prevention of duodenal ulcer recurrence, 20 mg at night. Initiate antisecretory therapy of Zollinger-Ellison syndrome with 20 mg every six hours and adjust to individual response. The maximum dosage used for up to one year was 480 mg daily.

CONTRA-INDICATION Hypersensitivity.

PRECAUTIONS Exclude any likelihood of gastric carcinoma before using 'Pepcid' PM. Consider reducing the daily dose if creatinine clearance falls to or below 30 ml/min. 'Pepcid' PM is not recommended in pregnancy, nursing mothers or children.

SIDE EFFECTS Rarely, headache, dizziness, constipation, diarrhoea. Less frequently, dry mouth, nausea, vomiting, rash, abdominal discomfort, anorexia, fatigue.

BASIC NHS COST 20 mg tablets, £14.00 for 28-day calendar pack and £25.00 for bottles of 50. 40 mg tablets, £26.60 for 28-day calendar pack and £47.50 for bottles of 50.

Product Licence Numbers:
20 mg tablets, 0025/0215; 40 mg tablets, 0025/0216.

Issued December 1989

® denotes registered trademark of Merck & Co., Inc., Rahway, NJ, USA

Thomas Morson Pharmaceuticals
Division of Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon, Herts., EN11 9BU

SPECIFICALLY DEVELOPED FOR THE SUPPRESSION OF NOCTURNAL ACID

08 90 PCD 89 GB 4393 J

STRENGTH AGAINST REFLUX[1]



In the management of reflux oesophagitis and hiatus hernia the role of Liquid Gaviscon is well established. Liquid Gaviscon deals with reflux simply and physically by forming a neutral layer or 'raft' on gastric contents to inhibit reflux and so bring effective relief of reflux-related upper gastro-intestinal symptoms.

More recently an in-vitro comparison[1] using computer-based techniques, has shown that Liquid Gaviscon produces a 'raft' more resistant to upward pressures than any other alginate-containing compound tested.

Liquid Gaviscon®

Sodium Alginate BPC, Sodium Bicarbonate Ph.Eur., Calcium Carbonate Ph.Eur.

a logical choice in reflux

Prescribing Information
Active Ingredients: Sodium Alginate BPC 500mg, Sodium Bicarbonate Ph.Eur. 267mg, Calcium Carbonate Ph.Eur. 160mg per 10ml dose. **Indications:** Heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia and reflux oesophagitis. **Contra-indications:** None known. **Dosage and Administration:** Adults, children over 12: 10-20ml liquid after meals and at bedtime. Children under 12: 5-10ml liquid after meals and at bedtime. Infants: not recommended.

Note: 10ml liquid contains 6.2mmol sodium. **Basis NHS Cost:** As at Jan. 1989: 500ml liquid £2.88. **PL:** 44/0058. **Irish Price IR** £3.72. **Irish P.A. No.:** 27/12/1.

Reference

1. Washington, N. *et al., Int. J. Pharmaceut.* (1986) **28,** 139-143

Further information is available on request.
Reckitt & Colman Pharmaceutical Division,
Hull HU8 7DS.
®Registered trade mark.

You don't have to go this far to treat acid reflux effectively

Zantac 300

RANITIDINE

The sooner the better

PRESCRIBING INFORMATION: INDICATIONS: Duodenal ulcer, benign gastric ulcer, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), oesophageal reflux disease, severe oesophagitis, chronic episodic dyspepsia. **DOSAGE:** *Adults:* Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. Alternatively, in duodenal ulcers, 300mg in the morning and evening for four weeks to achieve optimal healing. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Ulcers following non-steroidal anti-inflammatory drug therapy or associated with continued non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Chronic episodic dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Severe oesophagitis: 300mg four times daily for up to eight weeks (see data sheet for full dosage instructions). **CONTRA-INDICATIONS:** Patients with known hypersensitivity to ranitidine. **PRECAUTIONS:** Exclude the possibility of malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients with peptic ulcer and on NSAID therapy is recommended especially if elderly. Reduce dosage in the presence of severe renal failure (see data sheet). Like other drugs, use during pregnancy and lactation only if strictly necessary. **SIDE EFFECTS:** Headache, dizziness, skin rash, occasional hepatitis. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock. Rare cases of breast symptoms in men. As with other H_2-receptor antagonists rare cases of bradycardia, A-V block and asystole (see data sheet). **PRESENTATIONS:** Zantac 150 Tablets each containing 150mg ranitidine (Product Licence number 0004/0279, 60 tablets £29·76); Zantac 300 Tablets each containing 300mg ranitidine (Product Licence number 0004/0302, 30 tablets £27·43); Zantac Dispersible Tablets each containing 150mg ranitidine (Product Licence number 0004/0298, 60 tablets £31·25); Zantac Syrup each 10ml dose containing 150mg ranitidine (Product Licence number 0004/0310, 300ml bottle £22·32). **PRODUCT LICENCE HOLDER:** Glaxo Operations U.K. Limited, Greenford, Middlesex UB6 0HE.

Zantac is a Glaxo trade mark

Further information is available on request from:
Glaxo Laboratories Limited, Greenford, Middlesex UB6 OHE.
Tel: 081-422 3434

Glaxo

CYTOTEC
Abbreviated Prescribing Information
Presentation: Tablet containing misoprostol 200 micrograms.
Uses: Healing of duodenal and gastric ulcer induced by non-steroidal anti-inflammatory drugs (NSAID) in arthritic patients at risk, whilst continuing NSAID therapy. Prophylaxis of NSAID-induced ulcers. Healing of duodenal and gastric ulcer.
Dosage: Adults including the elderly. Healing of duodenal and gastric ulcer: 800 micrograms daily in two or four divided doses taken with breakfast and/or each main meal and at bedtime.
Prophylaxis of NSAID-induced ulcer: 200 micrograms twice daily, three times daily or four times daily. Refer to data sheet for additional information.
Contraindications: Pregnant women, women planning a pregnancy, patients allergic to prostaglandins.
Warnings: Pre-menopausal women should use effective contraception and be advised of the risks of taking Cytotec if pregnant.
Precautions: Cytotec does not produce hypotension in clinical studies at ulcer-healing doses, nevertheless exercise caution in disease states where hypotension might precipitate severe complications. Cytotec should not be administered during breast feeding.
Adverse effects: Diarrhoea, abdominal pain, dyspepsia, flatulence, nausea, vomiting, dizziness, skin rashes. [illegible] menorrhagia,

Soften the impact of NSAIDs on the stomach with prostaglandins

Cytotec is a prostaglandin analogue and therefore replaces G.I. prostaglandins depleted by NSAIDs.

Unlike H_2 receptor antagonists, Cytotec not only inhibits gastric acid secretion[1] but also protects the gastric mucosa by stimulating bicarbonate secretion,[2] increasing mucus secretion[1] and enhancing gastric mucosal blood flow.[3]

[illegible] misoprostol. Rajapaksha I, Adams A, Noar M. Dig Dis Sci 1986; 31 (suppl): 126S-129S.
2. Isenberg JI, Hogan DL, Koss MA, Selling JA. Gastroenterology 1986; 91: 370-378.
3. Sato N, Kawano S, Fukuda M, Tsuji S, Kamada T. Am J Med 1987; 83 (suppl 1A): 19-21.

ONLY

CYTOTEC®

misoprostol

SEARLE
GOLD CROSS
G.D. Searle & Co. Ltd., P.O. Box 53, Lane End Road, High Wycombe, Bucks. HP12 4HH

1. March 1990



Presentation: Each enteric-coated capsule contains 0.2ml peppermint oil Ph. Eur. **Uses:** Treatment of symptoms of irritable bowel syndrome. **Dosage and Administration:** Adult dose: 1-2 capsules three times a day, 30 minutes to one hour before food. Not to be taken immediately after food. The capsules should be taken until symptoms resolve, usually within one or two weeks. There is no experience of use in children under the age of 15 years. **Contra-indications, warnings, etc.** *Precautions:* Do not break or chew the capsules. Patients who already suffer from heartburn sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. Do not take indigestion remedies at the same time of day as this treatment. **Adverse effects:** Heartburn; sensitivity reactions to menthol, which are rare and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Pharmaceutical Precautions:** Store in a cool place. Avoid direct sunlight. **Legal category:** P. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** £12.15 per 100. **Date of issue:** September 1989. Colpermin is a Trade Mark. 9168018-04-90

Tillotts Laboratories, Italia House, Grosvenor Road, St Albans, Hertfordshire AL1 3AW

For Constipation

Fybogel Orange—gentle but effective
Fybogel Orange treats constipation gently but effectively by increasing bulk in the colon and thus encouraging normal, healthy peristalsis with soft, formed stools.[1]

Fybogel Orange—rapid first-line therapy
In a recent study of 224 newly presenting constipation patients treated with Fybogel Orange, 63.1% had a motion within 24 hours—and after 48 hours of Fybogel Orange 89.9% of patients had achieved bowel movement.[2]

Fybogel Orange—the patients' first choice for flavour
Recent tasting research showed that patients prefer orange flavoured bulking agents.[3]

Fybogel Orange

Ispaghula husk BP

gently does it

Active Ingredients: Each sachet contains 3.5g Ispaghula husk BP. **Indications:** Conditions requiring a high-fibre regimen. **Dosage and Administration:** (To be taken in water) Adults and children over 12: One sachet morning and evening. Children under 12: One half to one level 5ml spoonful depending on age and size, morning and evening. **Contra-indications, Warnings, etc.:** Fybogel is contra-indicated in cases of intestinal obstruction and colonic atony. **Basic NHS Price:** At April '88 60 sachets £4.24, Eire: 60 sachets IR £4.92. **PL No.:** Fybogel Orange 44/0068, Fybogel 44/0041. **Irish P.A. No.:** Fybogel Orange 27/2/2, Fybogel 27/2/1. **References:** 1. Data on file, 1985, Reckitt & Colman Pharmaceuticals. 2 Data on file, 1988, Reckitt & Colman Pharmaceuticals. 3. Data on file, 1987, Reckitt & Colman Pharmaceuticals. Fybogel is a trade mark. Further information is available from Reckitt & Colman Pharmaceuticals, Dansom Lane, Hull HU8 7DS.

Gentle, controlled release in Ulcerative Colitis

New Pentasa Slow Release Tablets... making the most of mesalazine

- "The release pattern of 5-ASA [mesalazine] preparations should, ideally remain unaffected by the intestinal transit time over a wide range. The results...indicate that PENTASA meets this requirement, as only 4% of 5-ASA is still retained in granules during normal conditions, and about 88% is released if the transit time is accelerated."[1]
- An advance in the treatment of inflammatory bowel disease.[2]

PENTASA
250mg
Mesalazine Tablets
NORDIC

Pentasa....Mesalazine, when and where it matters

Abridged Prescribing Information

Name of Product: PENTASA Slow Release Tablets. **Presentation:** Round, white to light grey mottled tablets with a break line on one side. Each tablet contains 250mg mesalazine in a slow release presentation. **Uses:** For the maintenance of remission in mild to moderate ulcerative colitis. **Dosage and administration:** Adults: The usual dose is two tablets, three times daily. **Contra-indications:** Children under the age of 15 years. Known sensitivity to salicylates. **Precautions, warnings etc:** PENTASA is not recommended in patients with renal impairment. Patients with raised blood urea or proteinuria should be treated with caution. PENTASA should be used with caution during pregnancy and lactation. Headache, diarrhoea and dyspepsia may occur in a small proportion of patients. Exacerbation of the symptoms of colitis may arise in patients who have previously had this problem with sulphasalazine. **Packing quantity:** Bottles containing 200 tablets. **Product Licence:** PL 3194/0043 **Basic NHS Price:** 200 x 250 mg tablets £32.28. **Product Licence Holder:** Ferring Pharmaceuticals Ltd, 11 Mount Road, Feltham, Middlesex. TW13 6JG. **Date of preparation:** March 1990. **Reference:** 1. Brit. J. Clin. Pharmac. (1987), 23: 365-369. 2. Ann. Intern. Med. (1988) 106: 911-912. **PENTASA is a registered trademark.**

Further information is available from: Nordic Pharmaceuticals, 11 Mount Road, FELTHAM, Middlesex. TW13 6JG. NORDIC

PRESCRIBING INFORMATION
PRESENTATION Ampoules of a white opaque emulsion containing diazepam BP 10mg in 2ml. INDICATIONS: 1. Sedation prior to procedures such as endoscopy, dentistry, cardiac catheterisation and cardioversion. 2. Premedication prior to general anaesthesia. 3. Control of acute muscle spasm due to tetanus or poisoning. 4. Control of convulsions; status epilepticus. 5. Management of severe acute anxiety or agitation including delirium tremens. DOSAGE AND ADMINISTRATION Diazemuls may be administered by slow intravenous injection (1ml per min), or by continuous infusion. Diazemuls should be drawn up into the syringe immediately prior to administration. 1. Sedation: 0.1 – 0.2mg diazepam/kg body weight by iv injection. 2. Premedication: 0.1 – 0.2mg diazepam/kg body weight by iv injection. 3. Tetanus: 0.1 – 0.3mg diazepam/kg body weight by iv injection repeated every 1-4 hours as required. Alternatively, continuous infusion of 3-10mg/kg body weight every 24 hours may be used. 4. Status epilepticus: An initial dose of 0.15 – 0.25mg/kg body weight by iv injection repeated in 30 to 60 minutes if required, and followed if necessary by infusion of up to 3mg/kg body weight over 24hr. 5. Anxiety and tension, acute muscle spasm, acute states of excitation, delirium tremens: The usual dose is 10mg repeated at intervals of 4 hours, or as required. Elderly or debilitated patients: Elderly and debilitated patients are particularly sensitive to benzodiazepines. Dosage should initially be reduced to one half of the normal recommendations. CONTRA-INDICATIONS, WARNINGS, ETC: As with other benzodiazepine preparations: should not be used in phobic or obsessional states nor in the treatment of chronic psychosis. Treatment with diazepam may cause drowsiness and increase the patient's reaction time. Use with caution in patients with impairment of renal or hepatic function and in patients with pulmonary insufficiency or myasthenia gravis. Should not be used alone to treat depression or anxiety associated with depression. Amnesia may occur. In cases of loss or bereavement psychological adjustment may be inhibited by benzodiazepines. Disinhibiting effects may be manifested in various ways. Suicide may be precipitated in patients who are depressed and aggressive behaviour toward self and others may be precipitated. Extreme caution should therefore be used in prescribing benzodiazepines in patients with personality disorders. Physiological and psychological symptoms of withdrawal including depression may be associated with discontinuation of benzodiazepines even after normal therapeutic doses for short periods of time. Pregnancy and Lactation: Diazepam crosses the placenta and should not be used during pregnancy unless considered essential. Large maternal doses administered during delivery may produce clinical effects in the newborn. Diazepam can be transmitted in breast milk and clinical effects may occur in the breast-fed infant. Side Effects: May rarely cause local pain or thrombophlebitis. Rare instances of a local painless erythematous rash around the site of injection. Urticaria and, rarely, anaphylaxis have been reported. Overdosage: CNS depression and coma. Treatment symptomatic. PHARMACEUTICAL PRECAUTIONS: See Data Sheet. Pack Size & Cost: 10 x 2ml ampoules: NHS Price £6.29. Product Licence No: 10183/0001. Date of preparation: June 1990. (Diazemuls is a registered trademark). Product Licence Holder: Dumex Ltd., Longwick Road, Princes Risborough, Aylesbury, Bucks HP17 9UZ. Tel: 0844 274414. Full prescribing information is available on request.

A gentle approach to I.V. sedation

DUMEX

Diazemuls®
10mg diazepam in 2ml emulsion

PREDICTABLE I.V. SEDATION · PREDICTABLE RECOVERY

SOME THINGS APPEAR TO BE SLIGHTLY DIFFERENT

Take for example peptic ulcers. For years people were convinced that the pathophysiology was related to gastric acid; healing no longer seemed to be a major problem, except for the high relapse rates.[1)]

In 1983 J.R. Warren and B.J. Marshall[2)] unearthed another pathological factor: Helicobacter pylori*. Since their historic rediscovery, evidence of the connection between H. pylori in the gastric mucosa on one hand and histologically proven gastritis and peptic ulcers on the other has become stronger and stronger. Chronic gastritis and ulcer relapse are highly associated with H. pylori.[3)]

De-Nol® is the only ulcer healer that is active against H. pylori. Therefore the relapse rates after termination of therapy are much lower than with acid-suppressant preparations.[4)] What is more: among patients in whom H. pylori was eradicated and who remained H. pylori negative in the year of follow-up, the relapse rate of peptic ulcers was only 0-10%.[4, 5, 6, 7, 8)]

The pathogenesis and cure of peptic ulcers therefore appear to be slightly different from what was assumed for years.

* formerly known as Campylobacter pylori

1. Marshall, B.J. Lancet 1988; i: 1437-42. 2. Marshall, B. Warren, R. Lancet 1984; i: 1311-15. 3. Graham, D.Y. Am J Gastroenterology 1989; 84: 1383-91. 4. Rauws, E.A.J., Tytgat, G.N.J. Lancet 1990; 335: 1233-35. 5. Rauws, E.A.J. et al. Gastroenterology 1988; 94: 33-40. 6. Penston, J.G. et al. Lancet 1991; 337: 473-77. 7. Borody, T.J. et al. Am J Gastroenterology 1989; 84: 1383-91. 8. Borody, T.J. et al. Gastroenterology 1991; 100: 1495-501.

Klean-Prep*

Polyethylene glycol 3350, sodium sulphate, sodium bicarbonate, sodium chloride, potassium chloride

Today's choice for a clean colon

for colonoscopy, colonic surgery, barium enema

- **Bowel cleansing** Superior bowel cleansing to standard regimens [1,2].
- **Safety** Negligible water and electrolyte disturbance [3].
- **Well tolerated** [1,2,4] Pleasantly flavoured.
- **Economy** Shortens preoperative stay [1,2,4].

Abbreviated Prescribing Information: Presentation: An off-white powder, packed in 4 sachets. Each sachet contains: Polyethylene Glycol 3350 59.00g, Sodium Sulphate 5.685g, Sodium Bicarbonate 1.685g, Sodium Chloride 1.465g, Potassium Chloride 0.7425g. **Uses:** Bowel preparation before colonoscopy, colonic surgery, radiological examination and other related procedures. **Dosage and Administration:** Reconstituted solution for oral administration. *Adults (including the elderly):* The contents of one sachet to be dissolved in 1 litre of water. 250ml to be drunk rapidly every 10-15 minutes until all the solution has been consumed. The procedure to be repeated with all four sachets or until the rectal effluent is clear. The solution from all 4 sachets should be drunk within 4-6 hours. No dosage changes need be made for patients with renal insufficiency. If administered by nasogastric tube the rate of administration should be 20-30ml/minute. *Children:* Not recommended. **Contra-indications, Warnings etc.** *Contra-indications:* Gastro-intestinal obstruction or perforation, ileus, gastric retention, acute intestinal or gastric ulceration, toxic colitis or megacolon. Patients with body weight less than 20kg. *Warnings:* Extra care should be taken in patients with impaired gag reflex, reflux oesophagitis, those with diminished levels of consciousness and in ulcerative colitis. *Interactions:* All oral medications should be given at least 1 hour prior to administration. *Side-effects:* Nausea, abdominal fullness, bloating may be experienced. Abdominal cramps, vomiting and anal irritation occur less frequently. These effects normally subside rapidly. Urticaria and allergic reactions have been reported rarely. Should distension or pain arise the rate of administration may be slowed. *Use in Pregnancy:* Careful consideration should be given before use in pregnancy. **Precautions:** The reconstituted solution should be refrigerated and used within 24 hours. Any unused portion should be discarded. **Package quantity:** Unit dose pack of 4 sachets. **Basic NHS price:** £8.60. PL 5628/0003 Licence holder: Birex Pharmaceuticals Ltd. Further information is available from Norgine Limited. *Klean-Prep is a trademark.

Distributed by NORGINE.

References 1 Fleites RA et al 1985 Surgery 98 4: 708-717; **2** Ernstoff JJ et al 1983 Gastroenterology 84 : 1512-1516; **3** Davis GR et al 1980 Gastroenterology 78 : 991-995; **4** Beck DE et al 1985 Southern Med J 78 : 1414-146.

Norgine Limited
116-120 London Road
Oxford OX3 9BA

For further information on Klean-Prep, please return this coupon to Norgine Ltd, FREEPOST (OF 676), Oxford OX3 9BR

NAME

ADDRESS



no compromise

After a thorough development programme and extensive clinical trials, we now have available a non-invasive test for ***Helicobacter pylori*** – an organism implicated in duodenal ulcer and gastritis.

Based on a well characterised antigen, developed by scientists at the Centre for Applied Microbiology and Research, **HELICO–G™** is an enzyme immunoassay that will quantify IgG antibodies to ***Helicobacter pylori.*** 95% of patients diagnosed with ***H pylori*** were correctly identified by **HELICO–G™**, proving it to be a consistent, high quality assay.

Convenient, rapid, reliable results, backed up by extensive clinical trial data, give you greater confidence.

Why compromise?

HELICO – G™

A SERO-DIAGNOSTIC KIT FOR DETERMINATION OF ANTIBODIES TO HELICOBACTER PYLORI IN HUMAN SERUM.

PORTON CAMBRIDGE

Porton Cambridge Ltd, Porton House,
Vanwall Road, Maidenhead,
Berks SL6 4UB, United Kingdom.
Tel. 0628–771417. Fax 0628–770211.

There are journals . . .

. . . and there are journals.

The only journal providing complete and systematic coverage of the entire discipline

Current Opinion in GASTROENTEROLOGY

- **Concise, critical and timely reviews**
- **Selected and annotated key papers**
- **Comprehensive bibliography**

EDITOR: IAD BOUCHIER

ISSN 0267-1379

Current Opinion in Gastroenterology

Please enter my subscription to Volume 6, 1990 (6 issues) at the following rate:

☐ Personal (from personal funds only) £50/US$80*
☐ Institutional £80/US$125*

Subscription rates include airspeed delivery

METHOD OF PAYMENT

☐ Am Ex ☐ VISA ☐ MasterCard Amount payable .....

Card no ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐ Exp date ☐☐☐☐

Signature ..... Date .....

☐ Cheque/Eurocheque enclosed payable to Current Science Ltd EX5
☐ Bank transfer (details available on request)

* Prices in US$ apply to subscribers in USA and Canada ONLY
£ sterling must be drawn on a UK bank, US$ on a US bank

☐ Please invoice (Institutional subscriptions ONLY)

Guarantee: Your money will be refunded if you write cancelling your subscription within 30 days of receiving the first issue.

Name .....
(BLOCK CAPITALS PLEASE)

Address .....

.....

Zip/Postcode ..... Country .....

☐ Please send me further information on Current Opinion in Gastroenterology Database

Return this form together with payment to:

In USA & Canada: CURRENT SCIENCE, Subscriptions, 20 North 3rd Street, Philadelphia, PA 19106-2113, USA or call TOLL FREE 1-800-552-5866 (in PA 215-574-2266)
Outside USA & Canada: CURRENT SCIENCE Ltd, Subscriptions, 34-42 Cleveland Street, London, W1P 5FB, UK
In Japan: Nankodo Co Ltd, 42-6 Hongo 3-chome, Bunkyo-ku, Tokyo 113, Japan
In India: Omega Scientific Publishers, 'Bookshelf', 29 Sunder Nagar Market, New Delhi 110003, India.


The others may be as effective*
But they cost up to 63% more†
TAGAMET
CIMETIDINE
800